Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Policy Screening Committee Proposes Major Cutbacks in Long-Listed Drug Prices, Additional Decreases Possible
November 24, 2011
- Patients’ Copayments for OTC-like Drugs to Be Increased on a Trial Basis: Policy Screening
November 24, 2011
- Council Approves New 10-Year Strategy for Hepatitis Research
November 24, 2011
- MHLW Council Approves Subsidizing Telaprevir Combination Therapy
November 24, 2011
- DPJ WT to Propose New Measures to Promote Generics
November 24, 2011
- Committee on OTC Drugs Recommends SSP’s Vaginal Candidiasis Treatment for Approval
November 24, 2011
- Korosho Issues Notification to Ensure Stable Supplies of Flu Drugs This Season
November 24, 2011
- Korosho’s Council Approves Subsidizing 3-Drug Combination Therapy Including Teraprevir
November 22, 2011
- MHLW Study Group Postpones Decision on Relief System for Victims of Health Damages Due to Anticancer Drugs
November 21, 2011
- After Delay, CSIMC Recommends Listing of Ilaris for Treatment of CAPS
November 21, 2011
- US FDA Revokes Avastin’s Approval for Metastatic Breast Cancer
November 21, 2011
- Former Chuikyo Chairman Prof. Endo Concerned about Increasing Drug Expenditure
November 21, 2011
- CSIMC Subcommittee Approves Special Price Reductions for Combination Drugs
November 18, 2011
- CSIMC Excludes DPC Flat-Sum Reimbursement, Recommends Approval for Reimbursement by Piecework for 5 APIs
November 18, 2011
- Korosho Approves 3 Switch OTC Products Containing Pemirolast
November 18, 2011
- Similar Products to Be Re-Priced by Product Following Market Expansion: CSIMC Expert Subcommittee
November 17, 2011
- Industry Renews Call for Perpetual Introduction of Premium for New Drug Development: CSIMC Expert Subcommittee
November 17, 2011
- Re-pricing of Essential Drugs Discussed at CSIMC
November 17, 2011
- CSIMC Recommends Listing of 9 Products Including Imusera; Recommendation Put on Hold for Ilaris
November 17, 2011
- Plaintiffs to Appeal Against “Unprecedented Unjust Ruling”: Iressa Appeal Trial
November 17, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…